Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05082051

Oral CDX-7108 in Healthy Adults and EPI Subjects

Exocrine Pancreatic Insufficiency Clinical Trial

Official title:
A 3-part, Phase 1a/1b, First-in-human, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral CDX-7108 in Healthy Adult Subjects and to Evaluate Proof-of-concept Via Pharmacodynamics of a Single Dose of Oral CDX-7108 in Subjects With Exocrine Pancreatic Insufficiency

Clinical Trial Summary

Phase 1a/1b single and multiple ascending dose study of oral CDX-7108 in healthy adult subjects and a single dose proof-of-concept study of oral CDX-7108 in subjects with exocrine pancreatic insufficiency. No clinical studies have yet been performed with CDX-7108 and its effects in humans are unknown. This is the first-in-human (FIH) study of CDX-7108, which aims to assess the safety, tolerability, pharmacokinetics (PK) of escalating single and multiple oral doses of CDX-7108 in healthy adult subjects and to evaluate the pharmacodynamics of a single dose of oral CDX-7108 in a proof-of-concept (POC) study in subjects with exocrine pancreatic insufficiency (EPI).

Clinical Trial Description

This is an integrated 3-part study to investigate the safety, tolerability, PK, and PD of CDX-7108. The Parts A and B are randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single and multiple oral dose administration in healthy adult subjects. Part C is a randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI. The study will commence with Part A (single ascending dose [SAD] study) and will progress to Part B (multiple ascending dose [MAD] study), and Part C (POC study) ;

Study Design

Related Conditions & MeSH terms

  • Exocrine Pancreatic Insufficiency
Clinical Trial Details
NCT number NCT05082051
Study type Interventional
Source Société des Produits Nestlé (SPN)
Contact
Status Completed
Phase Phase 1
Start date October 11, 2021
Completion date March 16, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Completed NCT03236038 - Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Completed NCT03407534 - Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating
Completed NCT02598128 - Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) N/A
Completed NCT00559364 - Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Phase 3
Completed NCT00408317 - Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT04548778 - BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency
Completed NCT00449878 - Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00981214 - Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00297167 - Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Recruiting NCT05480241 - Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Completed NCT02370537 - A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Phase 2
Completed NCT00559052 - An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) Phase 2
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Completed NCT06278272 - AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Completed NCT02734810 - SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Phase 3